Advanced search
1 file | 794.33 KB

Mechanisms and consequences of carbamoylation.

Sigurd Delanghe (UGent) , Joris Delanghe (UGent) , Reinhart Speeckaert (UGent) , Wim Van Biesen (UGent) and Marijn Speeckaert (UGent)
(2017) NATURE REVIEWS NEPHROLOGY. 13(9). p.580-593
Author
Organization
Abstract
Protein carbamoylation is a non-enzymatic post-translational modification that binds isocyanic acid, which can be derived from the dissociation of urea or from the myeloperoxidase-mediated catabolism of thiocyanate, to the free amino groups of a multitude of proteins. Although the term 'carbamoylation' is usually replaced by the term "carbamylation" in the literature, carbamylation refers to a different chemical reaction (the reversible interaction of CO2 with α and ε-amino groups of proteins). Depending on the altered molecule (for example, collagen, erythropoietin, haemoglobin, low-density lipoprotein or high-density lipoprotein), carbamoylation can have different pathophysiological effects. Carbamoylated proteins have been linked to atherosclerosis, lipid metabolism, immune system dysfunction (such as inhibition of the classical complement pathway, inhibition of complement-dependent rituximab cytotoxicity, reduced oxidative neutrophil burst, and the formation of anti-carbamoylated protein antibodies) and renal fibrosis. In this Review, we discuss the carbamoylation process and evaluate the available biomarkers of carbamoylation (for example, homocitrulline, the percentage of carbamoylated albumin, carbamoylated haemoglobin, and carbamoylated low-density lipoprotein). We also discuss the relationship between carbamoylation and the occurrence of cardiovascular events and mortality in patients with chronic kidney disease and assess the effects of strategies to lower the carbamoylation load.
Keywords
LOW-DENSITY-LIPOPROTEIN, STAGE RENAL-DISEASE, CHRONIC KIDNEY-DISEASE, CORONARY-ARTERY-DISEASE, MAINTENANCE DIALYSIS PATIENTS, RHEUMATOID-ARTHRITIS PATIENTS, SERUM MYELOPEROXIDASE LEVELS, TYPE-2 DIABETES-MELLITUS, LIPID-LOWERING THERAPY, HUMAN BLOOD MONOCYTES

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 794.33 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Delanghe, Sigurd, Joris Delanghe, Reinhart Speeckaert, Wim Van Biesen, and Marijn Speeckaert. 2017. “Mechanisms and Consequences of Carbamoylation.” Nature Reviews Nephrology 13 (9): 580–593.
APA
Delanghe, Sigurd, Delanghe, J., Speeckaert, R., Van Biesen, W., & Speeckaert, M. (2017). Mechanisms and consequences of carbamoylation. NATURE REVIEWS NEPHROLOGY, 13(9), 580–593.
Vancouver
1.
Delanghe S, Delanghe J, Speeckaert R, Van Biesen W, Speeckaert M. Mechanisms and consequences of carbamoylation. NATURE REVIEWS NEPHROLOGY. 2017;13(9):580–93.
MLA
Delanghe, Sigurd, Joris Delanghe, Reinhart Speeckaert, et al. “Mechanisms and Consequences of Carbamoylation.” NATURE REVIEWS NEPHROLOGY 13.9 (2017): 580–593. Print.
@article{8529596,
  abstract     = {Protein carbamoylation is a non-enzymatic post-translational modification that binds isocyanic acid, which can be derived from the dissociation of urea or from the myeloperoxidase-mediated catabolism of thiocyanate, to the free amino groups of a multitude of proteins. Although the term 'carbamoylation' is usually replaced by the term {\textacutedbl}carbamylation{\textacutedbl} in the literature, carbamylation refers to a different chemical reaction (the reversible interaction of CO2 with \ensuremath{\alpha} and \ensuremath{\epsilon}-amino groups of proteins). Depending on the altered molecule (for example, collagen, erythropoietin, haemoglobin, low-density lipoprotein or high-density lipoprotein), carbamoylation can have different pathophysiological effects. Carbamoylated proteins have been linked to atherosclerosis, lipid metabolism, immune system dysfunction (such as inhibition of the classical complement pathway, inhibition of complement-dependent rituximab cytotoxicity, reduced oxidative neutrophil burst, and the formation of anti-carbamoylated protein antibodies) and renal fibrosis. In this Review, we discuss the carbamoylation process and evaluate the available biomarkers of carbamoylation (for example, homocitrulline, the percentage of carbamoylated albumin, carbamoylated haemoglobin, and carbamoylated low-density lipoprotein). We also discuss the relationship between carbamoylation and the occurrence of cardiovascular events and mortality in patients with chronic kidney disease and assess the effects of strategies to lower the carbamoylation load.},
  author       = {Delanghe, Sigurd and Delanghe, Joris and Speeckaert, Reinhart and Van Biesen, Wim and Speeckaert, Marijn},
  issn         = {1759-5061},
  journal      = {NATURE REVIEWS NEPHROLOGY},
  keyword      = {LOW-DENSITY-LIPOPROTEIN,STAGE RENAL-DISEASE,CHRONIC KIDNEY-DISEASE,CORONARY-ARTERY-DISEASE,MAINTENANCE DIALYSIS PATIENTS,RHEUMATOID-ARTHRITIS PATIENTS,SERUM MYELOPEROXIDASE LEVELS,TYPE-2 DIABETES-MELLITUS,LIPID-LOWERING THERAPY,HUMAN BLOOD MONOCYTES},
  language     = {eng},
  number       = {9},
  pages        = {580--593},
  title        = {Mechanisms and consequences of carbamoylation.},
  url          = {http://dx.doi.org/10.1038/nrneph.2017.103.},
  volume       = {13},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: